Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
作者信息
Kastin A J, Barbeau A
出版信息
Can Med Assoc J. 1972 Dec 9;107(11):1079-81.
Abstract
The present study, carried out in 16 parkinsonian patients, indicates that L-prolyl-L-leucyl-glycine amide possesses some antiparkinsonian activity and that, if used with levodopa, it can reduce some of the drug-induced dyskinesias. These preliminary observations should be submitted to a controlled trial in a large number of patients before therapeutic applications are claimed.
摘要
相似文献
1
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Can Med Assoc J. 1972 Dec 9;107(11):1079-81.
2
High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Parkinsonism Relat Disord. 2005 Sep;11(6):393-8. doi: 10.1016/j.parkreldis.2005.03.005.
3
[Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia].
Prensa Med Mex. 1972 Jul-Aug;37(7):246-50.
4
The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
Confin Neurol. 1972;34(2):130-5.
5
[Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
Sist Nerv. 1970 Mar-Jun;22(2):82-91.
6
[Physiological trials with MIF-I in Parkinson's disease (author's transl)].
Rev Neurol (Paris). 1978 Feb;134(2):141-9.
7
The clinical use of levodopa in the treatment of Parkinson's disease.
Contemp Neurol Ser. 1971;8:175-201.
8
[Clinical study of L-dopa in Parkinson's disease].
Brux Med. 1972 Dec;52(12):851-60.
9
10
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Clin Neuropharmacol. 1990 Aug;13(4):303-11.
引用本文的文献
1
Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D Receptors.
ACS Med Chem Lett. 2023 Nov 14;14(12):1656-1663. doi: 10.1021/acsmedchemlett.3c00264. eCollection 2023 Dec 14.
2
Concepts for biologically active peptides.
Curr Pharm Des. 2010 Oct;16(30):3390-400. doi: 10.2174/138161210793563491.
3
Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor.
Eur J Pharmacol. 2010 Sep 1;641(2-3):96-101. doi: 10.1016/j.ejphar.2010.05.018. Epub 2010 May 27.
4
Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.
Drugs. 1973;6(5):364-88. doi: 10.2165/00003495-197306050-00004.
5
MSH-release inhibiting factors: recent studies.
Yale J Biol Med. 1973 Dec;46(5):617-22.
6
Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.
Can Med Assoc J. 1973 Oct 6;109(7):588-93.
7
The hypothalamus in Parkinson disease.
Ital J Neurol Sci. 1987 Jun;8(3):227-34. doi: 10.1007/BF02337479.
8
Neurohypophyseal hormones, analogs, and fragments: their effect on puromycin-induced amnesia.
Proc Natl Acad Sci U S A. 1975 Oct;72(10):4180-4. doi: 10.1073/pnas.72.10.4180.
9
Parkinson's disease, melanoma, and levodopa.
J Neurol. 1977 Jun 13;215(3):221-4. doi: 10.1007/BF00312480.
10
Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
Psychopharmacology (Berl). 1979 Jun 21;63(3):217-22. doi: 10.1007/BF00433553.
本文引用的文献
1
MELANOCYTE-STIMULATING HORMONE (MSH) AND ACTH ACTIVITIES OF PITUITARY HOMOGRAFTS IN ALBINO RATS.
Endocrinology. 1964 Aug;75:187-91. doi: 10.1210/endo-75-2-187.
2
[Antiparkinsonian agents. 1. New method of objective evaluation of rigidity and tremor in Parkinson's disease].
Union Med Can. 1962 Aug;91:842-7.
3
[Method of measurement of akinesia].
Union Med Can. 1966 May;95(5):531-5.
4
Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).
Ann Intern Med. 1970 Jan;72(1):29-35. doi: 10.7326/0003-4819-72-1-29.
5
Inhibition of MSH release in frogs by direct application of L-proplyl-L-leucylglycinamide to the pituitary.
Proc Soc Exp Biol Med. 1971 Sep;137(4):1437-9. doi: 10.3181/00379727-137-35805.
6
Adverse clinical side effects of levodopa therapy.
Contemp Neurol Ser. 1971;8:203-37.
7
Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF).
Proc Soc Exp Biol Med. 1972 Jul;140(3):811-4. doi: 10.3181/00379727-140-36558.
8
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).
Life Sci I. 1971 Nov 15;10(22):1279-83. doi: 10.1016/0024-3205(71)90326-2.
9
Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.
Can Med Assoc J. 1971 Jul 10;105(1):42-6 passim.
10
MSH activity in plasma and pituitaries of rats after various treatments.
Endocrinology. 1969 Jan;84(1):20-7. doi: 10.1210/endo-84-1-20.
Zotero 插件